Skip to main content
. 2021 Jul 27;13(1):1954136. doi: 10.1080/19420862.2021.1954136

Table 3.

Mean pharmacokinetic parameters for treatment groups of dostarlimab after intravenous infusion to monkeys at day 1 and day 22 in 1-month repeat-dose toxicology study

Dose (mg/kg) Study day Sex Cmax (μg/mL) Tmax (h) t1/2 (h) AUC0–168 (h*μg/mL)
10 1 Male 257 ± 77.8 0.5 (0.5–4.0) 260.1 (140.7–597.2) 17,700 ± 3870
Female 273 ± 27.2 0.5 (0.5–4.0) 211.9 (133.9–346.6) 19,800 ± 2620
Combined 265 ± 56.1 0.5 (0.5–4.0) 211.9 (133.9–597.2) 18,800 ± 3340
22 Male 451 ± 33.5 0.5 (0.5–0.5) 249.3 (191.3–424.3) 54,600 ± 5110
Female 488 ± 49.3 0.5 (0.5–4.0) 187.3 (175.3–542.3) 54,300 ± 8540
Combined 469 ± 44.5 0.5 (0.5–4.0) 217.8 (175.3–542.3) 54,400 ± 6710
30 1 Male 691 ± 76.6 0.5 (0.5–0.5) 184.5 (109.4–294.1) 54,300 ± 5730
Female 873 ± 77.6 4.0 (0.5–8.0) 137.7 (107.8–224.0) 68,000 ± 9350
Combined 782 ± 120 0.5 (0.5–8.0) 174.9 (107.8–294.1) 61,200 ± 10,300
22 Male 1260 ± 251 4.0 (0.5–8.0) 443.6 (111.8–810.2) 147,000 ± 57,700
Female 1380 ± 197 4.0 (0.5–8.0) 222.0 (192.9–438.6) 147,000 ± 22,100
Combined 1320 ± 224 4.0 (0.5–8.0) 318.2 (111.8–810.2) 147,000 ± 41,700
100 1 Male 2380 ± 475 0.5 (0.5–0.5) 227.5 (165.5–305.1) 193,000 ± 14,800
Female 2850 ± 718 0.5 (0.5–8.0) 144.1 (110.3–191.0) 201,000 ± 16,800
Combined 2620 ± 630 0.5 (0.5–8.0) 172.3 (110.3–305.1) 197,000 ± 15,600
22 Male 4080 ± 313 4.0 (4.0–8.0) 286.6 (161.2–468.6) 473,000 ± 69,000
Female 4060 ± 1470 0.5 (0.5–8.0) 175.3 (57.1–266.0) 365,000 ± 191,000
Combined 4070 ± 1010 4.0 (0.5–8.0) 212.8 (57.1–468.6) 419,000 ± 148,000

Data are presented as mean ± standard deviation for Cmax and AUC0–168 values, and median (range) for Tmax and t1/2 values. AUC0–168: area under the concentration–time curve from time 0 to 168 hours; Cmax: maximum concentration; t1/2: half-life; Tmax: time to Cmax.